Nevertheless, given the rarity of ALK fusions in CRC, larger-scale clinical studies are warranted to validate the influence of ALK fusions on the effectiveness of anti-EGFR inhibitors and to determine whether Bevacizumab could instead yield superior treatment outcomes. The gene discussed is EGFR; the disease is colorectal carcinoma.